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Abstract
NF-KB and the upstream kinase PKB/Akt are highly
expressed in chemoresistance tumor cells and may
hamper the apoptotic pathway. CF101, a specific ago-
nist to the A3 adenosine receptor, inhibits the develop-
ment of colon carcinoma growth in cell cultures and
xenograft murine models. Because CF101 has been
shown to downregulate PKB/Akt and NF-KB protein
expression level, we presumed that its combination
with chemotherapy will enhance the antitumor effect
of the cytotoxic drug. In this study, we utilized 3-[4,5-
Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) and colony formation assays and a colon
carcinoma xenograft model. It has been shown that a
combined treatment of CF101 and 5-fluorouracil (5-FU)
enhanced the cytotoxic effect of the latter on HCT-116
human colon carcinoma growth. Downregulation of
PKB/Akt, NF-KB, and cyclin D1, and upregulation of
caspase-3 protein expression level were observed in
cells and tumor lesions on treatment with a combina-
tion of CF101 and 5-FU. Moreover, in mice treated with
the combined therapy, myelotoxicity was prevented
as was evidenced by normal white blood cell and
neutrophil counts. These results show that CF101
potentiates the cytotoxic effect of 5-FU, thus prevent-
ing drug resistance. The myeloprotective effect of
CF101 suggests its development as an add-on treat-
ment to 5-FU.
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Introduction
Colorectal cancer is one of the most common human malig-
nancies and is considered as the leading cause of cancer
deaths. Surgery is the primary treatment option; however,
depending on the tumor stage and the involvement of lymph
nodes, 50% of patients will experience metastatic disease
progression [1]. Chemotherapy, mainly 5-fluorouracil (5-FU)
and leucoverin, is given to patients both in the adjuvant
setting and upon occurrence of metastasis. The mechanism
of action includes the metabolism of 5-FU to 5-fluoro-2V-
deoxyuridine monophosphate. The latter inhibits the
activity of thymidylate synthase, thereby decreasing dTTP
pools, leading to inhibition of DNA synthesis andG1/S cell cycle
arrest [2]. As a single agent, 5-FU is only modestly active,
producing a response rate of 15% in advanced colo-
rectal cancer. The standard protocol today is its administration
with leucoverin, which increases the cytotoxic effect of 5-FU
and avoids resistance to its thymidylate synthase–inhibitory
effects [3]. Adverse events upon 5-FU treatment, which include
damage to the bone marrow, skin, mucous membranes, intes-
tinal tract, and central nervous system, and cardiotoxicity, are
frequently recorded [4,5]. Today, additional combinations of
5-FU with oxaliplatin, irinotecan, paclitaxel, interferon-a, or
suramin are given as experimental protocols [6–9].
A3 adenosine receptor (A3AR) belongs to the family of the
Gi protein–associated cell surface receptors and it is highly ex-
pressed on the membrane of various tumor cell types [10–12].
CF101, a synthetic A3AR agonist, exerts a differential effect on
tumor and normal cells. It inhibits in vitro the growth of various
solid tumor cells and suppresses the development of mela-
noma, colon, and prostate carcinoma in experimental murine
models [13–15]. A major mechanism involved with the anti-
tumor effect of CF101 is deregulation of the NF-nB signal
transduction pathway. It was found that CF101 inhibits the
expression of PKB/Akt and NF-nB, followed by a decrease in
the binding of NF-nB to its DNA consensus sequence [16].
As a result, the transcription of gene products such as cyclin
D1 and c-Myc is downregulated [17,18].
It has been shown earlier that in tumor cells, high levels of
NF-nB and the upstream kinase PKB/Akt are known to act as
inhibitors of apoptosis, thus limiting the effect of chemotherapy
and leading to the development of drug resistance [19,20].
Interestingly, in parallel to its anticancer effect, CF101 acts
as a myeloprotective agent, through the induction of granulo-
cyte colony-stimulating factor (G-CSF) production [21]. More-
over, recent studies showed that A3AR agonists exert
cardioprotective and neuroprotective effects [22]. Based on
the above molecular mechanism of CF101 and its protective
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effects on normal body systems, the present study was
undertaken to examine the ability of CF101 to enhance the
cytotoxic effect of 5-FU on HCT-116 colon carcinoma cells
both in vitro and in vivo. The data obtained in this study
show that CF101 potentiates the cytotoxic effect of 5-FU
by downregulation of the NF-nB signaling pathway. In addi-
tion, CF101 prevents myelotoxic effects of 5-FU by rescuing
white blood cells (WBCs) and neutrophils.
Materials and Methods
Drugs
The A3AR agonist known generically as 1-deoxy-1-[6-
[[(iodophenyl)methyl]amino]-9H-purine-9-yl]-N-methyl-(-D-
ribofuranuronamide) (CF101),aGMPgrade,wassynthesized
for Can-Fite BioPharma by Albany Molecular Research, Inc.
(Albany, NY). A stock solution of 10 mM was prepared in
DMSO, and further dilutions in RPMI medium for in vitro
studies or in PBS for in vivo studies were performed. RPMI,
fetal bovine serum (FBS), and antibiotics for cell cultures
were purchased from Beit Haemek (Haifa, Israel). Primary
antibodies included rabbit polyclonals against the human
cell growth–regulatory proteins phosphorylated PKB/Akt
(p-PKB/Akt), NF-nB, cyclin D1, and caspase-3. All antibodies
were purchased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA) and served as primary antibodies.
The chemotherapeutic agent 5-fluorouracil (5-FU) was
purchased from ABIC (Petach-Tikra, Israel). 3-[4,5-yl]-2,5-
Dephenyltetrazolium bromide for the MTT assay was pur-
chased from Sigma (St. Louis, MO).
Tumor Cells
HCT-116 human colon carcinoma cells were used. Cells
were maintained in RPMI medium supplemented with 10%
FBS, 200 mM glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin. Cells were transferred to a freshly prepared
medium twice weekly.
MTT Assay
To determine the cytotoxic effect of 5-FU on HCT-116
colon carcinoma cells, different drug concentrations in the
range of 0.625 to 10 mM were used. EC50 was found at a
concentration of 2.5 mM. The efficacy of a combined treat-
ment of 5-FU + CF101 vs 5-FU alone was examined in the
HCT-116 colon carcinoma cell line. Cells (5  104 ml1)
were incubated with 1.25 and 2.5 mM 5-FU in 96-well micro-
titer plates. After 48 hours, CF101 at a concentration of
10 nM was added to the culture system. At the end of the
incubation period (72 hours total), MTT assay was used.
MTT stock solution (5 mg/ml) was added (1:10) to the cul-
ture system and incubated for 4 hours. Then the culture
medium was removed and MTT solvent (0.05 N HCl in
isopropanol) was added to the culture in an amount equal
to the original volume. Absorbance of the converted dye
was measured at 570 nm.
Colony Formation Assay
Exponentially growing HCT-116 cells were seeded at a
concentration of 1500 cells per 2-cm Petri dish and treated
with 5-FU (2.5 mM) or 5-FU + 10 nM CF101. Medium was
exchanged every 3 days. After 10 days, the cells were fixed
and stained with Giemsa (diluted 1/10 in PBS). Colonies
containing more than 50 cells were counted. For each
treatment, three Petri dishes were scored and the study
was repeated three times.
Protein Analysis by Western Blot Analysis
To assess the effect of the combined therapy (5-FU and
CF101) on the protein expression level of some cell growth–
regulatory proteins, HCT-116 cells were cultured in 10-cm
tissue culture plates (5  104/ml) with 2.5 mM 5-FU for
72 hours. After 48 hours, CF101 at a concentration of
10 nM was added to the culture system. At the end of the
incubation period, cell samples were rinsed with ice-cold
PBS and transferred to ice-cold lysis buffer (TNN buffer,
50 mM Tris buffer, pH 7.5, 150 mM NaCl, NP 40). The
trypsinized cells were washed again with ice-cold PBS,
harvested by centrifugation, and subjected to lysis in TNN
buffer. Cell debris was removed by centrifugation for
10 minutes at 7500g. The supernatant was utilized for WB
analysis. Protein concentrations were determined using the
Bio-Rad (Mu¨nchen, Germany) protein assay dye reagent.
Equal amounts of the sample (50 mg) were separated by
SDS-PAGE, using 12% polyacrylamide gels. The resolved
proteins were then electroblotted onto nitrocellulose mem-
branes (Schleicher and Schuell, Keene, NH). Membranes
were blocked with 1% bovine serum albumin and incubated
with the relevant primary antibody (dilution 1:1000) for
24 hours at 4jC. Blots were then washed and incubated
with the secondary antibody for 1 hour at room tempera-
ture. Bands were recorded using a color development kit
(Promega, Madison, WI).
In Vivo Studies
All the experiments were performed in accordance with
the Can-Fite Animal Care and Use Committee (Petach-
Tikva, Israel). Nude male Balb/C mice, aged 2 months and
weighing an average of 20 g, were obtained from Harlan
Laboratories (Jerusalem, Israel) and maintained on a stan-
dardized pelleted diet and supplied with tap water.
The effect of 5-FU in combination with CF101 on the
growth of human HCT-116 colon carcinoma cells in a xeno-
graft model was assessed. Cells (2  106) were subcuta-
neously injected to the flank of nude/BalbC mice. When
tumors reached a size off150 mm3, the mice were divided
randomly into three groups and treatment was initiated. Each
group contained 10 mice and the experiment was repeated
three times.
The following treatment protocol was utilized:
1. Control group—vehicle only
2. 5-FU—one cycle of intraperitoneal 5-FU (25 mg/kg),
given once a day for five consecutive days
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3. 5-FU + 10 mg/kg body weight CF101—CF101 treat-
ment was initiated 24 hours after the last 5-FU
injection until study termination.
Tumor size (width [W] and length [L]) was measured
twice weekly and was calculated according to the follow-
ing formula:
Tumor size ¼ W
2L
2
To test the myeloprotective effect of CF101, blood sam-
ples were withdrawn 48 hours after the initiation of CF101
treatment.
At the end of the study, tumor lesions from the three
groups were excised and homogenized (Polytron; Kinema-
tica, Littau-Lucerne, CH), and protein was extracted. WB
analysis was carried out to determine the expression level of
various cell growth–regulatory proteins.
Blood Cell Counts
WBC counts were carried out in a Coulter (Beckman
Coulter, Inc., Fullerton, CA) counter and neutrophil counts
were performed on smear preparations stained with May
Grunvald-Giemsa solution.
Statistical Analysis
The efficacy of the various agents in the in vitro and in vivo
study was evaluated using the Student’s t test. The criterion
for statistical significance was P < .05.
Results
Effect of 5-FU, in Combination with CF101, on the Growth
of HCT-116 Colon Carcinoma In Vitro and In Vivo
5-FU exerted an inhibitory effect on the growth of
HCT-116 cells in vitro as was measured by the thymidine
incorporation assay. The EC50 of 5-FU was detected at a
drug concentration of 2.5 mM (Figure 1A). The combined
treatment of 5-FU + CF101 yielded higher cell growth inhi-
bition in comparison to the chemotherapy alone (Figure 1B).
In cells treated with 2.5 mM 5-FU alone or in combination
with 10 nM CF101, colony formation was inhibited by
32.5 ± 4.87% and 57.3 ± 8.59%, respectively (Figure 2,
A and B ). In a different set of experiments, we showed that
treatment with 5-FU + CF101 yielded a higher inhibitory
effect (48 ± 7.2%) on the growth of HCT-116 human colon
carcinoma xenografts in nude mice in comparison to 5-FU
alone (29 ± 4.35%, P < .001) (Figure 3).
CF101 Prevents the Myelotoxic Effect of 5-FU
Mice treated with 5-FU alone exhibited a 42.9 ± 0.6%
decline in the number of WBC and a 81 ± 0.9% decline in
neutrophil count. The administration of CF101 following 5-FU
treatment counteracted the myelotoxic effect of 5-FU, result-
ing in a 13.7 ± 0.5% decline in the number of WBC and a
29.1 ± 0.1% decline in neutrophil counts (Figure 4, A and B ).
Effect of 5-FU + CF101 on the Expression Level of Cell
Growth–Regulatory Proteins in HCT-116 Human Colon
Carcinoma Cells and Tumor Lesions
To explore the molecular mechanism involved with the
enhancement of the chemotherapeutic effect by CF101, we
assessed the expression of the cell growth–regulatory pro-
teins PKB/Akt, NF-nB, and cyclin D1. These proteins are
known from our former studies to be modulated upon CF101
treatment. Because caspase-3 is located downstream to
PKB/Akt and is upregulated prior to apoptosis, its protein
expression level was assessed as well.
A similar protein profile was detected in protein extracts
from cell culture and tumor lesions depicting downregulation
of PKB/Akt, NF-nB, and cyclin D1 upon treatment with 5-FU +
CF101 in comparison to 5-FU. The level of caspase-3 was
upregulated in the combined treatment (Figure 5). These
results support the notion that CF101 acts in vitro and in vivo
Figure 1. Effect of 5-FU + CF101 on the growth of colon carcinoma cells
in vitro. (A) HCT-116 human colon carcinoma cells were incubated
with different 5-FU concentrations for 72 hours. An MTT assay was
preformed to detect cell growth. (B) HCT-116 human colon carcinoma
cells were incubated with 5-FU (1.25 and 2.5 M) in the presence or ab-
sence of 10 nM CF101 for 72 hours. An MTT assay was preformed to detect
cell growth.
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through a similar molecular mechanism to mediate the
enhancement of 5-FU effects.
Discussion
This study presents data showing that a combined treatment
of 5-FU + CF101 potentiates the inhibitory effect of the
cytotoxic drug both in vitro and in vivo.
In vitro, we utilized two assays: the first entailed the MTT
assay, which represents cytotoxic effects; and the second
examined the ability of the colon carcinoma cells to form
colonies, simulating the establishment of tumor lesions
in vivo. It was shown that CF101 enhanced the cytotoxic
effects as well as the antiproliferative effects of 5-FU. It was
further noted that in HCT-116 tumor-bearing mice, the com-
bined treatment of 5-FU + CF101 yielded higher tumor
growth inhibition than chemotherapy alone, confirming the
ability of CF101 to potentiate 5-FU effects.
To explore the underlined molecular mechanism, we
followed up the protein expression level of cell growth–
regulatory proteins known to be responsible for tumor cell
resistance to chemotherapy.
Overexpression of PKB/Akt and NF-nB in tumor cells
plays a role in cell resistance to chemotherapeutic agents,
resulting in failure of the tumor cells to undergo apoptosis.
PKB/Akt, a cell survival kinase, is located upstream to
NF-nB and is activated in a broad spectrum of neoplasms
[23]. PKB/Akt is known to control the NF-nB level by phos-
phorylating downstream proteins (IKK and InB), which in turn
release NF-nB from its complex [24]. NF-nB then trans-
locates to the nucleus where it induces the transcription of
growth factors including TNF-a and the oncogene cyclin D1
[25]. The latter was found to be directly related to chemo-
resistance. In SW620 colon carcinoma cells overexpressing
Figure 2. Effect of CF101 + 5-FU on the development of colon carcinoma
colony development in vitro. HCT-116 cells were incubated with 5-FU in the
presence and absence of 10 nM CF101. Medium was exchanged every
3 days and the cells were allowed to form colonies over a period of 10 days.
At the end of the experiment, the plates were stained with Giemsa and
colonies greater then 50 cells were counted (A). Representative plate from
each treatment is presented (B).
Figure 3. Effect of CF101 + 5-FU on the growth of HCT-116 human colon
carcinoma cells in nude mice. HCT-116 human colon carcinoma cells (2 106)
were subcutaneously injected to the flank of nude mice. Treatment with 5-FU
alone (25mg/kg, i.p., once daily for five consecutive days), or in combination with
CF101 (10 g/kg, p.o., twice daily), was initiated when the tumor reached a size
off150 mm3. Tumor size was measured twice weekly.
Figure 4. Effect of CF101 + 5-FU treatment on the number of WBC and ANC
in colon carcinoma–bearing mice. HCT-116 human colon carcinoma tumor–
bearing mice were treated with 5-FU alone (25 mg/kg, i.p., once daily for
five consecutive days), or in combination with CF101 (10 g/kg, p.o., twice
daily, starting 48 hours after last 5-FU treatment). The number of WBC (A)
and neutrophils (B) was analyzed.
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cyclin D1, resistance to apoptosis induced by cisplatin was
observed usingmicroarray analysis [26]. Moreover, inhibition
of cyclin D1 expression was shown to modulate the effect
of antineoplastic drugs through alterations in the expression
level of drug resistant genes. Kornmann et al. demonstrated
that suppression of cyclin D1 expression after a stable
transfection with cyclin D1 antisense construct in PANC-1
and COLO-357 human pancreatic cancer cells resulted in
decreased levels of the chemoresistance gene products
MDR-1 and MRP. This led to a significant increase in
sensitivity to 5-FU and mitoxantrone [27].
Furthermore, Uetsuka et al. [28] have shown that elimi-
nation of NF-nB activity induced apoptosis and reduced
chemoresistance to 5-FU. It is thus clear that upregulation
of NF-nB is directly and indirectly linked to cell proliferation
and inhibition of apoptosis. PKB/Akt controls additional
apoptotic pathways including GSK-3b, caspase-9, and
caspase 3, which, upon PKB/Akt activation, are modulated,
thereby failing to activate pathways leading to apoptosis
[29]. Evidence to support the role of PKB/Akt in controlling
the resistance of tumor cells to apoptosis came from studies
in which transfection of constitutively active PKB/AKT in lung
cancer cells reduced topotecan-induced apoptosis [30],
whereas inactivation of PKB/AKT enhanced apoptosis in-
duced by SN-38, doxorubicin, and etoposide [31–33].
In the present study, treatment of HCT-116 cells with
5-FU + CF101 resulted in decreased levels of PKB/Akt,
NF-nB, and cyclin D1, whereas the apoptotic protein
caspase-3 was upregulated. A similar pattern of the re-
sponse was shown in tumor lesions excised from the 5-FU +
CF101–treated mice, confirming that the above signaling
proteins are involved with the enhanced chemotherapeutic
effect of CF101.
We have recently shown that CF101, given as a mono-
therapy to melanoma-, colon carcinoma–, or prostate
carcinoma–bearing mice, inhibited tumor development
through the downregulation of NF-nB and cyclin D1. These
data strengthen the results reported in the present study
and enlighten the molecular mechanism described above.
Myelotoxicity, mainly granulocytopenia, is dose-limiting
in most chemotherapeutic drug treatments, including 5-FU
[34]. In this study, we show that CF101, on top of its
capability to potentiate the antitumor effect of 5-FU, pre-
vented the decrease in WBC and neutrophils upon 5-FU
treatment. Our earlier studies have shown that CF101
induces the production of G-CSF by mononuclear cells.
Interestingly, this characteristic of CF101 was found to be
mediated through the upregulation of NF-nB—the only
transcription factor of G-CSF. This was concluded based
on ex vivo data showing that in splenocytes derived from
CF101-treated mice, upregulation of PI3K, PKB/Akt, IKK,
and IkB occurred, leading to increased NF-nB level and
G-CSF production.
It thus seems that in the present study, a differential ef-
fect of CF101 on tumor and normal cells is observed and is
most probably mediated through the ability of CF101 to
inhibit NF-nB levels in tumor cells and stimulate it in normal
cells (such as G-CSF–producing cells). To conclude,
CF101, an orally bioavailable molecule, potentiates the
cytotoxic effect of 5-FU toward tumor cells through a
mechanism that ‘‘opens the gate’’ for apoptosis to occur.
Concomitantly, CF101 prevents the myelotoxic effect of
Figure 5. Effect of CF101 + 5-FU treatment on the expression of cell growth– regulatory proteins in colon carcinoma cells. Immunoblots showing the effect of 5-FU
alone, or in combination with CF101, on the expression level of PKB/Akt, NF-jB, cyclin D1, and caspase-3 in HCT-116 cell cultures (left) or tumor lesions (right) are
presented. Culture conditions and experimental colon carcinoma model are as described in legends to Figures 1 and 3, respectively.
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chemotherapy by rescuing the number of WBC and neutro-
phils. CF101 may be suggested as an ‘‘add on’’ to 5-FU in
the treatment of colon carcinoma.
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